Market Research Logo

Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: About this market

Technavio’s Duchenne muscular dystrophy (DMD) therapeutics market analysis considers sales from both biologics and small molecules in Asia, Europe, North America, and ROW. In 2018, the biologics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high efficacy to stop the progression of the disease will play a significant role in the biologics segment to maintain its market position. Also, our global DMD therapeutics market report looks at factors such as high unmet need, increasing strategic alliance, and patient assistance programs. However, high treatment costs, stringent regulatory environment, and adverse side effects of DMD therapeutics may hamper the growth of the DMD therapeutics industry over the forecast period.

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Overview

High unmet need.

Duchenne muscular dystrophy led to the identification of the dystrophin gene, which is responsible for coding patients that helps in maintaining muscle cell membrane stability. This led to the identification of various therapeutic targets, such as dystrophin-based therapies like EXONDYS 51 and TRANSLARNA. However, the high costs of these drugs are restricting their penetration in many underdeveloped and developing countries. This has resulted in high unmet demand for affordable therapies that can reverse the progression of DMD. This is encouraging many leading vendors to introduce affordable novel therapies for the treatment. The strong distribution network of vendors coupled with the presence of reimbursement policies will lead to the expansion of the global Duchenne muscular dystrophy (DMD) therapeutics market at a CAGR of over 37% during the forecast period.

Increasing research funding

Advances in diagnostic methods is leading researchers and organizations to conduct research onresearch developing therapeutics for treating DMD. For instance, Muscular Dystrophy Association developed an innovative way to fund the research on moving new drug targets into clinical stages at a fast pace. On the other hand, organizations such as Duchenne UK provides research grants to vendors and researchers developing therapeutics for DMD. This increasing research funding is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global Duchenne muscular dystrophy (DMD) therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of a few major players, the global Duchenne muscular dystrophy (DMD) therapeutics market is highly concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading Duchenne muscular dystrophy (DMD) therapeutics manufacturers, that include F. Hoffmann-La Roche Ltd., PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., Wave Life Sciences Ltd.

Also, the Duchenne muscular dystrophy (DMD) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.


PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
The threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
Biologics - Market size and forecast 2018-2023
Small molecules - Market size and forecast 2018-2023
Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-202
Key leading countries
Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 12: MARKET TRENDS
Strong pipeline
Increasing research funding
Special drug designations
PART 13: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 14: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
F. Hoffmann-La Roche Ltd.
PTC Therapeutics Inc.
Santhera Pharmaceuticals
Sarepta Therapeutics Inc.
Wave Life Sciences Ltd.
PART 15: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Global DMD therapeutics market pipeline: Overview
Exhibit 19: Global DMD therapeutics market pipeline: Snapshot
Exhibit 20: Type - Market share 2018-2023 (%)
Exhibit 21: Comparison by type
Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 51: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 52: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 53: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 54: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 55: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 56: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 57: PTC Therapeutics Inc. - Vendor overview
Exhibit 58: PTC Therapeutics Inc. - Business segments
Exhibit 59: PTC Therapeutics Inc. - Organizational developments
Exhibit 60: PTC Therapeutics Inc. - Key offerings
Exhibit 61: PTC Therapeutics Inc. - Key customers
Exhibit 62: Santhera Pharmaceuticals - Vendor overview
Exhibit 63: Santhera Pharmaceuticals - Business segments
Exhibit 64: Santhera Pharmaceuticals - Organizational developments
Exhibit 65: Santhera Pharmaceuticals - Geographic focus
Exhibit 66: Santhera Pharmaceuticals - Key offerings
Exhibit 67: Santhera Pharmaceuticals - Key customers
Exhibit 68: Sarepta Therapeutics Inc. - Vendor overview
Exhibit 69: Sarepta Therapeutics Inc. - Business segments
Exhibit 70: Sarepta Therapeutics Inc. - Organizational developments
Exhibit 71: Sarepta Therapeutics Inc. - Geographic focus
Exhibit 72: Sarepta Therapeutics Inc. - Key offerings
Exhibit 73: Sarepta Therapeutics Inc. - Key customers
Exhibit 74: Wave Life Sciences Ltd. - Vendor overview
Exhibit 75: Wave Life Sciences Ltd. - Business segments
Exhibit 76: Wave Life Sciences Ltd. - Organizational developments
Exhibit 77: Wave Life Sciences Ltd. - Key offerings
Exhibit 78: Wave Life Sciences Ltd. - Key customers
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: Definition of market positioning of vendors

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report